MOVES-Barclays makes new appointments in healthcare banking group
(Adds Apostolatos, other healthcare deals)
Dec 15 (Reuters) - Barclays Plc (LSE: BARC.L - news) said on Tuesday it
had hired two senior dealmakers in the United States as it seeks
to expand its healthcare investment banking group amid a frenzy
of dealmaking in the sector.
Ben Taylor, previously head of emerging pharmaceutical
companies at Goldman Sachs Group Inc, has joined
Barclays' team in New York. He has a 15-year career spanning
New York, California, Europe and Asia. In one of his previous
roles, he was co-head of healthcare for Goldman's China and
South East Asia investment banking business.
Christine Poon, previously a vice chair and worldwide chair
of pharmaceuticals at Johnson & Johnson Inc, was named
senior adviser to Barclays' healthcare banking group. She (Munich: SOQ.MU - news) will
be responsible for further developing relationships and
strategic dialogue with key healthcare clients.
After retiring from Johnson & Johnson (NYSE: JNJ - news) , Poon spent five years
as dean of the Max M. Fisher College of Business at the Ohio
State University, the first to be appointed directly from the
private sector since the institution was founded in 1916.
Before joining Johnson & Johnson, Poon spent 15 years at
Bristol-Myers Squibb Co in various roles including
president of international medicines.
Other recent additions to the Barclays healthcare team
include Nicholas Apostolatos, who left Morgan Stanley (Xetra: 885836 - news)
earlier this year to join the British bank in New York.
Barclays has lost talent too in what has been a record year
for healthcare mergers, led by Pfizer Inc (NYSE: PFE - news) 's $160 billion
acquisition of Allergan Plc (NYSE: AGN - news) . Earlier this year, a group
of five healthcare bankers led by Punit Mehta left Barclays to
work at Credit Suisse Group AG.
Nevertheless, Barclays has had a role on several of this
year's top healthcare deals, including advising Teva
Pharmaceutical Industries Ltd on its acquisition of a
generic drug portfolio from Allergan for $40.5 billion.
Barclays also advised Endo International Plc (NasdaqGS: ENDP - news) on its
$8.05 billion acquisition of Par Pharmaceutical Holdings Inc, as
well as CareFusion Corp on its $12.2 billion sale to Becton,
Dickinson & Co.
(Reporting by Greg Roumeliotis in New York; Editing by Matthew
Lewis and Cynthia Osterman)